Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria. - Wikidata - wikimedia - TriplyDB

Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

http://www.wikidata.org/entity/Q37383670

about

Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Use of quantitative pharmacology tools to improve malaria treatments.What is the best size predictor for dose in the obese child?Modelling the impact of antimalarial quality on the transmission of sulfadoxine-pyrimethamine resistance in

P2860

Q31153944-740B0CF0-3DA2-419C-AB38-F5A0061DF7D9 Q36018444-1C83A4B7-B6AE-4E77-B6C7-8E1AFD3B65F0 Q37096787-D3B41E4E-C995-4F4F-BBCC-8D8767102E10 Q37279764-48AD2F59-08DC-4A83-AFD0-01B709FE7FCF Q38664529-AB5CBAC0-EE0C-49F8-8187-EFEA17215E9F Q47179401-2A3B08E2-AD73-4735-B6F8-C8F872DB680E Q56440042-46D0ED14-26CD-4F35-844A-F6CFDAD8E894

P2860

Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

http://www.wikidata.org/entity/Q37383670

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 May 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Population Pharmacokinetics of ...... ine for Uncomplicated Malaria.

@en

Population Pharmacokinetics of ...... ine for Uncomplicated Malaria.

@nl

type

label

Population Pharmacokinetics of ...... ine for Uncomplicated Malaria.

@en

Population Pharmacokinetics of ...... ine for Uncomplicated Malaria.

@nl

prefLabel

Population Pharmacokinetics of ...... ine for Uncomplicated Malaria.

@en

Population Pharmacokinetics of ...... ine for Uncomplicated Malaria.

@nl

P1433

Q37383670-6D83A123-1D7F-49AB-9E14-E0EF86AA3CCE

P1476

Q37383670-9D153FB6-9D65-499F-842C-9AAE6B2B68A1

P2093

Q37383670-2600E8F5-508C-4A36-85E9-D8EEC8991D28

Q37383670-2A4A516D-95D5-4049-A143-D1B840052260

Q37383670-36E07118-3363-4788-B369-9F8FF154275D

Q37383670-5357D2A4-93DB-48B1-8AB1-EB521E26CAEA

Q37383670-54014E76-6828-455D-9E50-E9E0BB9ED990

Q37383670-7FCF68E9-205D-4093-A328-1731F8CF38F9

Q37383670-993693D2-AF1A-4CE8-9CB0-38FB9011F138

Q37383670-B970CC22-098A-468B-9A3C-43D343D4F254

Q37383670-BA6BB24D-8CCF-4514-9B1B-F267E9FD4785

Q37383670-C1E08064-EFC0-4B6A-B24A-075BF50DD321

P2860

Q37383670-0DFCB22D-AAE6-4F61-8919-0FB26B2A0869

Q37383670-0F2D4F27-D39F-4693-B712-BB51C6894FC6

Q37383670-136061D8-DEA5-4763-AA75-89DC7D318D45

Q37383670-1A67CDF4-864C-4E35-AE6C-F3DE7C66D596

Q37383670-2957837A-2F66-40FE-BFBC-7FBAEEBEA971

Q37383670-3802BF50-655C-497C-8455-2D5D0876F2E4

Q37383670-3E707CB8-9758-4BE6-80BB-3B06DB5DBCFC

Q37383670-450E5D3B-BC45-4008-8D4F-5A6AE5CD5F53

Q37383670-49D05F92-62A4-45D2-89ED-BC01E91CD7CA

Q37383670-543DAE65-3E50-4B3E-8CED-C96D7C0AECCA

P304

Q37383670-76C7A4F3-4744-4950-B080-A961A23A8A36

P31

Q37383670-545C0083-C524-4382-A2DE-AF6C782E1972

P356

Q37383670-684A2038-BD9D-4115-AC4F-C66B0478A2D6

P407

Q37383670-5A140C36-C385-42E8-81AB-DC9314BC5CC4

P433

Q37383670-0BE23CA9-71FF-46F3-AD51-3AE9E2167CF3

P478

Q37383670-4EED93C0-6723-47B5-96CD-90E0E907D292

P50

Q37383670-220F410E-59B0-494E-AF3F-1784653E870A

Q37383670-D4F1FE93-E4BE-4066-BC77-0B346F8A7A64

P577

Q37383670-4092845D-4DFD-4DFA-AA1E-A2D2661ABA39

P698

Q37383670-281FDB6F-72D3-409C-B736-25F7AE2172A0

P921

Q37383670-559FACB1-3918-4D44-B377-F04A5056AFB5

Q37383670-EBB4AD6A-D14C-4AFA-8444-3AB5B275E690

P932

Q37383670-F6734A55-75B9-456A-9E7F-7BC6BF89363D

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Population Pharmacokinetics of ...... ine for Uncomplicated Malaria.

@en

P2093

A Kakuru

http://www.w3.org/2001/XMLSchema#string

E Arinaitwe

http://www.w3.org/2001/XMLSchema#string

F T Aweeka

http://www.w3.org/2001/XMLSchema#string

H Wanzira

http://www.w3.org/2001/XMLSchema#string

J Tarning

http://www.w3.org/2001/XMLSchema#string

J W Tappero

http://www.w3.org/2001/XMLSchema#string

L Yan

http://www.w3.org/2001/XMLSchema#string

N C Sambol

http://www.w3.org/2001/XMLSchema#string

N Lindegardh

http://www.w3.org/2001/XMLSchema#string

S A McCormack

http://www.w3.org/2001/XMLSchema#string

P2860

Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaedit

The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children

Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis

Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

Drug interactions of HIV protease inhibitors.

Effects of a high-fat meal on the relative oral bioavailability of piperaquine

Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval

P304

87-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.104

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

François H Nosten

P577

2015-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25732044

http://www.w3.org/2001/XMLSchema#string

P921

P932

5088713

http://www.w3.org/2001/XMLSchema#string